VBCF | Vienna BioCenter Core Facilities

HomeFacilities

WELCOME TO THE VIENNA BIOCENTER CORE FACILITIES

Access to state-of-the-art research infrastructure and scientific services.

WELCOME TO THE VIENNA BIOCENTER CORE FACILITIES

Access to state-of-the-art research infrastructure and scientific services.

WELCOME TO THE VIENNA BIOCENTER CORE FACILITIES

Access to state-of-the-art research infrastructure and scientific services.

We enable scientists to achieve their goals by providing access to cutting-edge research infrastructure in the field of biomedical research.

We keep our resources, technology, and expertise at the highest level in order to stay at the forefront of science.

The Vienna Biocenter Core Facilities (VBCF) have been publicly funded by the Austrian Federal Ministry of Education, Science and Research, and the City of Vienna via Vienna Business Agency.

Our shareholders are Vienna BioCenter, MFPL, IMBA, and GMI.

Shareholders

Funding Bodies

News

Network

Downloads

Selected publications

The 'PhenoBox', a flexible, automated, open-source plant phenotyping solution

Czedik-Eysenberg, A., Seitner, S., Güldener, U., Koemeda, S., Jez, J., Colombini, M., & Djamei, A.

2018, The New phytologist.

Dorsal tegmental dopamine neuron gate associative learning of fear.

Groessl F., Munsch T., Meis S., Griessner J., Kaczanowska J., Pliota P., Kargl D., Badurek S., Kraitsy K., Rassoulpour A., Zuber J., Lessmann V., Haubensak W.

2018, Nat. Neuroscience 21(7):952-62.

Baculovirus-driven protein expression in insect cells: A benchmarking study.

Stolt-Bergner P, Benda C, Bergbrede T, Besir H, Celie PHN, Chang C, Drechsel D, Fischer A, Geerlof A, Giabbai B, van den Heuvel J, Huber G, Knecht W, Lehner A, Lemaitre R, Nordén K, Pardee G, Racke I, Remans K, Sander A, Scholz J, Stadnik M, et al.

2018, J. Struct. Biol. 2018 Mar 12.

Genetically engineered cerebral organoids model brain tumor formation

Bian S, Repic M, Guo Z, Kavirayani A, Burkard T, Bagley JA, Krauditsch C & Knoblich JA

2018, Nat. Methods. 2018 Aug; 15(8): 631-639

SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis

Muhar M, Ebert A, Neumann T, Umkehrer C, Jude J, Wieshofer C, Rescheneder P, Lipp JJ, Herzog VA, Reichholf B, Cisneros DA, Hoffmann T, Schlapansky MF, Bhat P, von Haeseler A, Köcher T, Obenauf AC, Popow J, Ameres SL, Zuber J

2018, Science. 2018 May 18

Dr Daniele Soroldoni

Managing Director

+43-1-796 23 24 7010

E-Mail

VBC2 / PG7

We enable scientists to achieve their goals by providing access to cutting-edge research infrastructure in the field of biomedical research.

ACCESS FOR FACILITIES' USERS

News

Ubiquitin & Friends 2019: symposium in Vienna

Audio portrait of IMP Group Leader Clemens Plaschka

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Vienna BioCenter at the ball of sciences

Open Access to selected VBCF services until exploitation of available funds!

10 Million Euros for Access to European Proteomics Facilities

Obituary: Andreas Weith (1953 to 2019), former IMP Group Leader

Official opening of the new Electron Microscope Glacios

Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Valneva Announces its Intention to Delist from the Vienna Stock Exchange

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate

New Managing Director at VBCF

Austrian-Czech project provides open access to research infrastructure

VBC Summer School 2019 application deadline: 31 January 2019

Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance

Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus

Large infrastructure project PHENOPlant for phenotyping of crop plants approved

New website for Vienna BioCenter

WE BRING YOU NEW KNOWLEDGE - TAKE ADVANTAGE OF IT!

Network

PROJECT & GRANTS

Downloads

Selected publications

Management

RESEARCH INFRASTRUCTURES – A KEY INSTRUMENT IN ADVANCEMENT OF KNOWLEDGE AND TECHNOLOGY

Contact